RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
Admissions From EDs Increased for FFS Beneficiaries in 2020
In 2020, the total number of emergency department (ED) visits for Medicare fee-for-service (FFS) beneficiaries declined, but patients presenting with non-emergency care sensitive conditions were more likely to be admitted than in 2019.
Utilization Management Trends in the Commercial Market, 2014–2020
A new Avalere analysis examines the prevalence of utilization management (UM) in the commercial market from 2014 to 2020, focusing on drugs treating cancer, autoimmune diseases, and a range of other chronic conditions.
Digital Health Advances Create Opportunities for Access and Engagement
Digital health solutions continue to advance the way healthcare is delivered. Through research and development as well as stakeholder partnerships, life science companies can leverage digital health technologies to optimize access along the patient care journey.
Rare and Orphan Disease Therapies Require New Distribution Strategies
Manufacturers currently in the developmental phase for drug assets targeting rare or orphan diseases should assess the commercialization implications when bringing novel therapies to market and how they may differ from the standard pharmaceutical supply chain and economics.
Webinar: Looking Ahead: The Evolving Oncology Landscape
Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.
AI in Healthcare: Raise the Evidence Bar Now or Be Forced to Later
In 2012, experts predicted that artificial Intelligence (AI) would eventually replace as much as 80% of current clinical practice by physicians. While AI has certainly expanded in healthcare—especially during the COVID-19 pandemic—the last few years have included some eventful setbacks in the use of AI across several sectors of the economy, including healthcare.
Interview: Infusing the Patient Perspective into Value Assessment, Part III
Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In the final segment of our series on infusing the patient perspective into value assessment, our experts discuss the Patient Perspective Value Framework (PPVF) developed by Avalere Health and FasterCures, which employs a form of multi-criteria decision analysis to capture value according to patients.
Video: COVID-19 and Oncology Care
Tune into another episode in the Avalere Health Essential Voice series focused on disease education. In this segment, experts from Community Oncology Alliance (COA) and Texas Oncology join us to discuss the impact of COVID-19 on oncology care from a provider and patient perspective.
Interview: COVID-19 and Oncology Care
Tune into another episode in the Avalere Health Essential Voice podcast series focused on disease education. In this segment, experts from Community Oncology Alliance (COA) and Texas Oncology join us to discuss the impact of COVID-19 on oncology care from a provider and patient perspective.
Inovalon Data Powers New Insights on Diverse Healthcare Populations
Data-driven research presented at Academy of Managed Care Pharmacy (AMCP), ISPOR annual meeting, and key spring conferences powered by Inovalon’s MORE2 Registry® Dataset
Interview: Infusing the Patient Perspective into Value Assessment, Part II
Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In this segment, we continue our series on infusing the patient perspective into value assessment with a discussion on the need for a solution to incorporating value drivers outside of traditional endpoints, and introduce a proposed approach to quantify those elements of healthcare value.
Interview: Infusing the Patient Perspective into Value Assessment, Part I
Tune into another episode of Avalere Health Essential Voice in our Start Your Day with Avalere series. In this segment, our experts kick off a three-part series about patient perspective in value assessment with an overview of value assessments and value frameworks.
Interview: Senior Health and Well-Being During COVID-19
Tune into another episode in the Avalere Health Essential Voice podcast series focused on COVID-19. In this segment, Richard Ashworth, President and CEO of Tivity Health, joins us to discuss survey findings around COVID-19 and the senior population, with key takeaways related to vaccination acceptance and hesitancy.
Medicare FFS Utilization Decreased During the COVID-19 Pandemic
Avalere analysis finds healthcare utilization among Medicare Fee-for-Service (FFS) beneficiaries decreased in the spring of 2020 compared to the spring of 2019.
A Data-Driven Approach to Identifying Patients with AAD
On November 4, Avalere experts presented “Development of a Claims-Based Algorithm to Identify Patients with Agitation in Alzheimer’s Dementia” at the Gerontological Society of America Annual Scientific Meeting.
COVID-19 Impacts on Cancer Care
Avalere research was published online in the Journal of Clinical Oncology Clinical Cancer Informatics, showing a considerable drop in cancer screening, diagnosis, and treatment for Medicare beneficiaries as a result of the ongoing COVID-19 pandemic.
Hospital Discharges to Home Health Rebounding, But SNF Volumes Lag
New Avalere Health analysis of Medicare fee-for-service (FFS) claims data reveals large decreases in skilled nursing facility (SNF) and home health care use following the widespread decline in inpatient hospitalizations amid the response to the COVID-19 pandemic. Avalere’s analysis further suggests that as inpatient procedures resume in some areas, the volume of inpatient hospital discharges to home health is starting to rebound, whereas the volume of discharges to SNF remains below 2019 levels.
New Data Approaches for Novel Curative Therapies and APMs
On June 9, Avalere experts discussed new data analytics and approaches for evaluating value-based topics in healthcare in the “New Data Approaches for Novel Curative Therapies & APMs” webinar. They examined the current approaches to assessing the value of treatments, novel curative therapy affordability and access, and the role of data in healthcare decision-making.
COVID-19 Hospitalizations Projected to Cost up to $17B in US in 2020
Avalere analysis of Medicare fee-for-service (FFS) hospital stay claims with associated COVID-19 diagnoses finds that total US healthcare system costs for hospitalizations due to COVID-19 could range from $9.6B to $16.9B in 2020.
Decline in Oncology and Immunology Treatment Amid COVID-19 Pandemic
Recent Avalere analysis finds decreases in utilization of oncology and autoimmune treatments across all care settings since the onset of the health crisis.